Daré Bioscience (NASDAQ:DARE) and Pasithea Therapeutics (NASDAQ:KTTA) Financial Survey

Pasithea Therapeutics (NASDAQ:KTTA) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Institutional & Insider Ownership

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 4.0% of Daré Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Pasithea Therapeutics and Daré Bioscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	$20,000.00	203.20	-$15.96 million	N/A	N/A
Daré Bioscience	$2.84 million	9.63	-$30.16 million	($0.59)	-5.42

Pasithea Therapeutics has higher earnings, but lower revenue than Daré Bioscience.

Profitability

This table compares Pasithea Therapeutics and Daré Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-81.57%	-74.31%
Daré Bioscience	-191.65%	N/A	-18.68%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Pasithea Therapeutics and Daré Bioscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	0	0	0	0	0.00
Daré Bioscience	0	2	2	0	2.50

Daré Bioscience has a consensus target price of $24.00, suggesting a potential upside of 650.00%. Given Daré Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Pasithea Therapeutics.

Volatility & Risk

Pasithea Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Summary

Daré Bioscience beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

About Daré Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.